SCN1B and Dravet syndrome: In particular, the presence of pyramidal neuron hyperexcitability at low current injections in Scn1b−/− mice suggests that treatment with K+ channel activators may be beneficial in EIEE52 patients, as suggested previously,22 whereas VGSC blockers should remain contraindicated, as is the case in DS patients.35